The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma-Reference-Cited by-同舟云学术

The Tumor Immune Microenvironment Is Associated With Recurrence in Early-Stage Lung Adenocarcinoma

Published:2024-04 Issue:4 Volume:5 Page:100658
ISSN:2666-3643
Container-title:JTO Clinical and Research Reports
language:en
Short-container-title:JTO Clinical and Research Reports

Author:

Kanemura Hiroaki,Yokoyama Toshihide,Nakajima Ryu,Nakamura Atsushi,Kuroda Hiroaki,Kitamura Yoshitaka,Shoda Hiroyasu,Mamesaya Nobuaki,Miyata Yoshihiro,Okamoto Tatsuro,Okishio Kyoichi,Oki Masahide,Sakairi Yuichi,Chen-Yoshikawa Toyofumi Fengshi,Aoki Tadashi,Ohira Tatsuo,Matsumoto Isao,Ueno Kiyonobu,Miyazaki Takuro,Matsuguma Haruhisa,Yokouchi Hideoki,Otani Tomoyuki,Ito Akihiko,Sakai Kazuko,Chiba Yasutaka,Nishio Kazuto,Yamamoto Nobuyuki,Okamoto Isamu,Nakagawa Kazuhiko,Takeda Masayuki

Publisher

Elsevier BV

Reference35 articles.

1. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer;Goldstraw;J Thorac Oncol,2016

2. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J Clin Oncol,2008

3. Evolution of systemic therapy for stages I–III non-metastatic non-small-cell lung cancer;Chaft;Nat Rev Clin Oncol,2021

4. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial;Felip;Lancet,2021

5. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial;O’Brien;Lancet Oncol,2022